Cargando…
Real‐world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network
AIMS: To explore the prevalence and describe the clinical characteristics of people with type 2 diabetes with a similar cardiovascular (CV) profile to that of the LEADER trial participants in a primary care setting in England. MATERIALS AND METHODS: In this cross‐sectional analysis, using the Royal...
Autores principales: | Hinton, William, Feher, Michael, Munro, Neil, Walker, Megan, de Lusignan, Simon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6619442/ https://www.ncbi.nlm.nih.gov/pubmed/30900349 http://dx.doi.org/10.1111/dom.13710 |
Ejemplares similares
-
Does Real World Use of Liraglutide Match its Use in the LEADER Cardiovascular Outcome Trial? Study Protocol
por: Hinton, William, et al.
Publicado: (2018) -
Fenofibrate as a COVID-19 modifying drug: Laboratory success versus real-world reality
por: Feher, Michael, et al.
Publicado: (2021) -
How Generalizable Are Cardiovascular Outcome Trials of Sodium-Glucose Co-Transporter-2 Inhibitors? A National Database Study: Study Protocol
por: Hinton, William, et al.
Publicado: (2019) -
Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
por: McGovern, Andrew, et al.
Publicado: (2017) -
Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes: Protocol for a Kidney End Points Real-world Study (COMBi-KID Study)
por: Feher, Michael, et al.
Publicado: (2022)